HOME
ABOUT
About US
Corporate culture
Company honor
Development course
PRODUCT
Drugs in the field of tumor-re
Drugs in other fields
Health care products
R&d innovation
R&d pipeline
R&d progress
Patient recruitment
NEWS
Company dynamics
Trade news
Academic exchanges
INVESTOR
Latest announcement
H&R
Job development
Talent recruitment
CONTACT
Notice
EN
CN
HOME
ABOUT
About US
Corporate culture
Company honor
Development course
PRODUCT
Drugs in the field of tumor-re
Drugs in other fields
Health care products
R&d innovation
R&d pipeline
R&d progress
Patient recruitment
NEWS
Company dynamics
Trade news
Academic exchanges
INVESTOR
INVESTOR
Latest announcement
H&R
Job development
Talent recruitment
CONTACT
Notice
Shengbai Oral Liquid (Mixture) was included in the "2018 Clinical Pathway Therapeutic Drug Interpretation: Tumor Disease Volume" anti-tumor Chinese patent medicine
2018-11-12
PREV
Overview of the research on the prevention and treatment of leukopenia after chemoradiotherapy
NEXT
Shengbai Oral Liquid (Mixture) was included in the "2018 Clinical Pathway Therapeutic Drug Interpretation: Blood Diseases Volume" for the treatment of Chinese patent medicines for blood diseases
Hot news
What kind of treatment is needed fo...
How to deal with leukopenia after c...
Should I stop chemotherapy if I h...
Should leukopenia be discontinued i...
Shengbai Oral Liquid (Mixture) w...
Shengbai oral liquid (mixture) was ...
How much do you know about leukopen...
Shengbai Oral Liquid: Progress a...